Tag: 上海品茶网AQM

Sage’s epilepsy drug fails to do better than placebo in key clinical trial

first_img @adamfeuerstein Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Log In | Learn More Senior Writer, Biotech Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He’s also a co-host of “The Readout LOUD” podcast. Sage Therapeutics’ closely watched drug, brexanolone, did not do much better than a placebo in helping patients with a severe type of epilepsy, data from a phase 3 clinical trial show.Sage, which is based in Cambridge, Mass. expected brexanolone to lead to its first-ever drug approval. Instead, its shares dropped 25 percent to $66 in pre-market trading. Sage’s epilepsy drug fails to do better than placebo in key clinical trial By Adam Feuerstein Sept. 12, 2017 Reprints Biotech STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What’s included?center_img Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED About the Author Reprints Adam Feuerstein Tags biotechnologydrug developmentrare disease GET STARTED [email protected] What is it? David and Mary Logan believe Sage’s drug helped him, but it failed in a clinical trial. Alissa Ambrose/STATlast_img read more

Read More